RECEIVED CENTRAL FAX CENTER

Fax

APR 0 3 2006



Eli Lilly and Company Lilly Corporate Centre Indianapolls, Indiana 46285 U.S.A.

Date: 3 April 2006

To:

D. Jiang

Company:

USPTO

Fax:

571-273-8300

Technology Center 1600

From: Greg Cox

Fax: 317-276-5172 Phone: 317-277-2620

Total Pages: 5

Privileged and Confidential Communication

RE:

Serial No. 10/679,746

Group Art Unit: 1646

Confirmation: 8224

Docket No.:

X-11921A

CONFIDENTIALITY NOTICE: This fax message from Eli Lilly and Company (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply fax and destroy all copies of the original message.

Please contact Jan Fowler at 317-655-1715 if you incur any difficulties with this transmission.

RECEIVED CENTRAL FAX CENTER

APR 0 3 2006

	CERTIFICATION OF FACSIN	MILE TRANSMISSION		
I hereby certify that this pape	r is being facsimile transmitted to the Patent	and Trademark Office on the dai	te shown below.	
·	JANET	FOWLER		
,	Type or print name of person	signing certification		,
	Cant. Fun	1,1	0.6	
··· · · · · ·	Signature	Date	<u> </u>	

<u>PATENT APPLICATION</u> IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Yakubu-Madus, et al.)	
Serial No.	ï	10/679,746)	
Filed	:	October 6, 2003)	Group Art Unit: 1646
For	:	Synergistic use of Thiazolidinediones with Glucagon-Like Peptide-I and Agonists Thereof to Treat Metabolic Instability Associated with Non-Insul)	Examiner: D. Jiang
		Dependent Diabetes)	Confirmation: 8224
Docket No.	;	X-11921A)	

RESPONSE TO RESTRICTION AND/OR ELECTION REQUIREMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

An Election Requirement was set forth in an Office Action mailed March 7, 2006 for the patent application captioned above.

Claims 23-47 are pending in the present application.

Applicants respectfully request that the Examiner consider the following arguments against a restriction requirement.

Claims are reproduced for the Examiner's convenience and begin on page 2 of this paper.

Remarks begin on page 4 of this paper.